CV Therapeutics ranolazine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Each of three dose levels of sustained-release ranolazine "was associated with statistically significant (p<0.005) increases in patients' treadmill exercise duration with no clinically meaningful effects on blood pressure or heart rate compared to placebo" in a pivotal trial, the company reported at the 49th annual meeting of the American College of Cardiology. The multicenter, double-blind MARISA (Monotherapy Assessment of Ranolazine In Stable Angina) study randomized 191 patients withdrawn from other anti-anginal drugs to 500 mg, 1000 mg, or 1500 mg ranolazine b.i.d. or placebo for a four-period study. Patients received each of the treatments for a seven-day period in a Latin square crossover design. Exercise testing with a modified Bruce protocol programmed into treadmills was performed at trough (12 hours after dosing) and peak (four hours after dosing). Results for 175 patients who completed three or four of the treatment periods showed exercise duration at trough of 559 seconds for the 1500 mg dose, 545 seconds for 1000 mg and 533 seconds for 500 mg vs. 511 seconds for placebo (p<0.001, p<0.001 and p=0.003, respectively). Time to angina at trough was 472 seconds (1500 mg), 457 seconds (1000 mg) and 437 mg (500 mg) vs. 412 seconds for placebo (p<0.001, p<0.001 and p=0.005). A second pivotal trial, CARISA, will test the drug in combination with other anti-angina agents. Results are expected next year
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.